NCT06880380招募中1 期
The Efficacy and Safety Study of CAR-T Cells for Functional Cure in HIV-1/AIDS Patients
Institute of Hematology & Blood Diseases Hospital, China1 个研究点 分布在 1 个国家目标入组 3 人开始时间: 2025年9月1日最近更新:
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 3
- 试验地点
- 1
- 主要终点
- Incidence of adverse reactions
研究概览
简要总结
Autologous CAR-T cell therapy in HIV-1/AIDS patients
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age between 18 and 65 years;
- •Confirmed diagnosis of HIV-1 infection, with regular antiviral therapy ≥24 months prior to enrollment and sustained HIV-RNA levels <50 copies/mL for the 12 months preceding enrollment;
- •CD4+ T-cell count >350/μl within 30 days prior to enrollment;
- •Female participants of childbearing potential (including those ≤50 years old who are amenorrheic) must have a negative urine pregnancy test; from the screening period until the end of the study, participants should have no plans for conception and must voluntarily adopt effective contraceptive measures;
- •Willingness to provide true identity information and comply with follow-up requirements;
- •Ability to fully understand the study objectives, procedures, and potential risks, voluntary signing of an informed consent form, and adherence to the study requirements.
排除标准
- •Women who are pregnant, breastfeeding, or of childbearing potential unwilling/unable to use effective contraception.
- •Coinfection with other viruses or infections, including HIV-2, HAV, HBV, HCV, HDV, HEV, EBV, CMV, or syphilis.
- •History of AIDS-related opportunistic infections or malignancies within the past year (e.g., candidiasis, coccidioidomycosis, cryptococcosis, cytomegalovirus disease, herpes simplex, lymphoma).
- •Autoimmune diseases requiring systemic immunosuppressive/immunomodulatory therapy within the past 2 years (e.g., Crohn's disease, rheumatoid arthritis, systemic lupus erythematosus).
- •Severe non-AIDS-related comorbidities, including uncontrolled clinically significant diseases of the genitourinary, cardiovascular, respiratory, neurological, psychiatric, gastrointestinal, endocrine, immune systems, or malignancies.
- •Central nervous system (CNS) disorders, such as epilepsy, cerebral ischemia/hemorrhage, dementia, cerebellar diseases, or autoimmune conditions involving the CNS.
- •Suspected or confirmed history of alcohol abuse, drug addiction, illicit substance use, or psychiatric disorders.
- •Abnormal laboratory results within 14 days prior to enrollment meeting any of the following:
- •Hemoglobin <10 g/dL (female) or <11 g/dL (male) Absolute neutrophil count <1 ×10⁹/L Platelet count <100 ×10⁹/L Serum creatinine >110 μmol/L INR >1.5 or PTT >45 seconds ALT or AST >2.5 × upper limit of normal (ULN) Total bilirubin >1.5 × ULN
- •Current participation in another clinical trial that may conflict with the current protocol or outcome assessments.
- •Any other condition deemed inappropriate for participation by the investigator.
研究组 & 干预措施
CAR-T
Experimental
干预措施: HIV-CAR-T (Biological)
结局指标
主要结局
Incidence of adverse reactions
时间窗: Up to 12 Weeks After CAR T-cell Infusion
次要结局
- HIV-1 RNA level(Up to 12 Weeks After CAR T-cell Infusion)
研究者
研究点 (1)
Loading locations...
相似试验
Unknown
1 期
Third-Generation CAR-T-cell Therapy in Individuals With HIV-1 InfectionHIV-1NCT04863066Beijing 302 Hospital8
招募中
1 期
The Effect of Chimeric Antigen Receptor (CAR)-T Cell Therapy on the Reconstitution of HIV-specific Immune FunctionHIV/AIDSNCT03240328Guangzhou 8th People's Hospital40
撤回
1 期
Novel CAR-T Cell Therapy in the Treatment of Hematopoietic and Lymphoid MalignanciesAcute Myeloid Leukemia (AML)B-cell Non-Hodgkin's Lymphoma (B-NHL)Multiple Myeloma (MM)T-Cell Leukemia/Lymphoma, AdultB-cell Acute Lymphoblastic Leukemia (B-ALL)NCT05513612Shanghai Pudong Hospital
尚未招募
1 期
A Study of CAR-T Cells in Subjects with Autoimmune DiseasesAutoimmune DiseasesNCT06762119Zhejiang University6
尚未招募
早期 1 期
B7-H3 Targeting CAR-T Cells Therapy for B7-H3 Positive Solid TumorsAdvanced Solid TumorNCT05515185The First People's Hospital of Lianyungang30